白念珠菌天冬氨酸蛋白酶基因SAP2在大肠杆菌中的表达及产物纯化

目的构建SAP 2重组原核表达载体并表达、纯化出可溶性的蛋白,为抗体制备及Sap2抗原检测奠定基础。方法提取白念珠菌基因组DNA为模板,经PCR方法获取SAP 2目的基因。双酶切SAP 2基因与原核表达载体pMAL-c2x(+),连接酶切产物,转化大肠杆菌TOP10感受态细菌,筛选菌落和测序鉴定。将pMAL-c2x/SAP2重组质粒转化大肠杆菌BL21(DE3)感受态细胞,经异丙基硫代-β-D-半乳糖苷(IPTG)诱导表达出可溶性的融合蛋白,经直链淀粉树脂亲和层析、蛋白酶Factor Xa切割标签获得纯化的Sap2蛋白。结果经PCR扩增获得正确的SAP 2序列并定向插入原核表达载体pMAL-c2x(+)中。重组原核表达载体pMAL-c2x/SAP2经IPTG诱导14 h后表达出可溶性的融合蛋白,并经纯化、切除标签后得到目的蛋白。结论成功构建了白念珠菌天冬氨酸蛋白酶原核表达质粒pMAL-c2x/SAP2,该质粒在BL21(DE3)中可获得高效融合表达,通过亲和层析纯化及标签切割得到了氨基酸序列同天然蛋白一致的目的蛋白。     

大鼠热休克蛋白70的融合表达及纯化鉴定

目的：在大肠杆菌中高效表达并纯化大鼠热休克蛋白（HSP）70与麦芽糖结合蛋白（MBP）的融合蛋白,以进一步研究细胞外HSfr70的生物学功能。方法：用RT-PCR方法扩增目的基因,并将其克隆到原核表达载体pMAL-c2X中,酶切鉴定并进行DNA测序;将该重组表达载体转化大肠杆菌B121,用IPTG在不同温度及时间下进行诱导表达,建立最佳诱导表达条件;采用Amylose树脂预装柱对目的蛋白进行亲和纯化,并对不同表达条件下的产物进行SDS-PAGE及Westernblot分析。结果：克隆出目的基因,构建了融合表达载体pMAL-c2X／hsp70;诱导表达后经SDS-PAGE检测表明获得了目的条带,并纯化出纯度较高的融合蛋白;免疫印迹鉴定表明其具有抗原活性。结论：在大肠杆菌中高效表达并纯化了融合蛋白MBP-HSP70,为进一步研究细胞外HSP70的生物学效应提供了有用的材料。     

黑芝麻多酚氧化酶的重组表达及其酶学特性

为明确黑芝麻多酚氧化酶的酶学性质,利用大肠杆菌Escherichia coli原核表达了黑芝麻多酚氧化酶 (Black sesame polyphenol oxidase,BsPPO)。将合成的基因构建至pMAL-c5x载体,并在大肠杆菌中进行表达,对重组蛋白进行分离纯化及融合标签切除,获得的BsPPO蛋白用于酶学性质探究。结果表明,合成的Bsppo基因1 752 bp,编码585个氨基酸,理论蛋白分子量为65.3 kDa;构建的pMAL-c5x-Bsppo重组质粒在大肠杆菌Escherichia coli BL21(DE3) 中可溶表达了MBP-BsPPO蛋白;酶切去除MBP融合标签后对BsPPO进行了酶学性质研究,结果表明BsPPO的最适温度和pH分别为25 ℃和4.0,在低温和弱酸性环境中有较好的稳定性。短时间低强度的光照和Cu2+可激活BsPPO的活性,Zn2+和Ca2+能抑制其活性。BsPPO可催化单酚、二酚以及三酚类化合物,对l-酪氨酸以及香草酸表现出较高的催化活性,此外BsPPO还对黑芝麻中含有的2-甲氧基肉桂酸、吲哚3-羧酸和根皮素表现出良好的催化活性。研究结果为黑芝麻多酚氧化酶酶学特性的明确奠定了理论基础。     

人Hepassocin的原核可溶性表达与纯化

目的：构建人Hepassocin的原核表达载体,可溶性表达并纯化得到高纯度的重组人Hepassocino方法：将人Hepassocin基因克隆到原核表达载体pET40b（＋）,转化大肠杆菌BL21（DE3）,于28℃经0．1mmol／LIPTG诱导6h,表达Ds-bC-Hepassocin融合蛋白,经镍柱纯化可溶性融合蛋白,用肠激酶切除融合蛋白的DsbC-His标签,再用镍柱纯化分离酶切后的Hepassocin,通过超滤进一步纯化并浓缩,用Western blot验证纯化后的Hepassocin。结果：构建了pET40b-Hepassocin原核表达载体,经诱导表达、亲和层析和肠激酶切除融合标签,获得了相对分子质量约32000的可溶性高纯度蛋白,Western blot鉴定证实该蛋白为不含融合标签的重组人Hepassocin。结论：实现了人Hepassocin的原核可溶性表达,通过纯化获得了较高纯度的重组人Hepassocin,为制备其单克隆抗体,进一步研究其生物学功能奠定了基础。     

肉毒毒素蛋白受体syt II N端片段基因的合成及其在大肠杆菌中的融合表达

本研究旨在构建肉毒毒素蛋白受体sytII N端片段的原核表达载体,并在大肠杆菌pMAL-c2x系统中表达MBP-Syt融合蛋白。根据GenBank中已报道的人syt II基因序列,截取N端氨基酸序列,依据大肠杆菌的偏爱密码子,设计引物人工合成全基因,将全长基因克隆至原核表达载体pMAL-c2x中,重组质粒转化大肠杆菌E.coli ER2566,IPTG诱导表达。表达产物经Amylose Resin亲和层析进行纯化,SDS-PAGE和免疫印记对其进行鉴定,并对该蛋白进行活性的初步分析,为进一步研究毒素与受体相互作用的机制奠定基础。     

幽门螺杆菌Lpp20融合蛋白的表达、标签切除及鉴定

目的:利用GST融合基因表达系统表达Lpp20-GST融合蛋白,并利用凝血酶切除GST标签.方法:IPTG诱导重组质粒Lpp20/pGEX-4T -1在大肠杆菌BL21 (DE3)中表达,菌体经反复冻融、溶菌酶裂解及超声破菌后,发现Lpp20-GST融合蛋白以部分可溶性的形式表达.采用GST蛋白纯化系统对其纯化,得到Lpp20- GST融合蛋白,再用凝血酶进行GST标签的切除,所得产物进行Western Blot鉴定.结果:高效表达出Lpp20-GST融合蛋白的相对分子质量约4.5kDa,凝血酶成功切除了GST标签,Western Blot证实Lpp20蛋白能被鼠抗Lpp20单克隆抗体识别.结论:成功表达和纯化了重组Lpp20蛋白,为深入研究Lpp20的功能奠定了基础.     

甘油脱水酶β亚基融合蛋白在大肠杆菌中的表达和纯化

为了表达及纯化甘油脱水酶β亚基蛋白,采用PCR及DNA重组技术将甘油脱水酶β亚基基因gldB重组到含麦芽糖结合蛋白(MBP)的融合蛋白表达载体pMAL-c2x中,在大肠杆菌中进行表达。结果表明,转化重组质粒pMAL/gldB的大肠杆菌经IPTG诱导,SDS-PAGE分析显示：表达出的MBP-glddB融合蛋白相对分子质量约72000,与预期大小一致,并经Western blot分析证实。进一步通过直链淀粉树脂亲和层析纯化得到电泳均一的融合蛋白。已获得的重组甘油脱水酶β亚基蛋白有利于研究其生物学性能。     

磷脂酰肌醇特异性磷脂酶C的异源表达和应用

旨在研究大肠杆菌产磷脂酰肌醇特异性磷脂酶C(PI-PLC)的发酵表达和分离纯化,探究PI-PLC酶切GPI锚定蛋白的效果。依据NCBI数据库中蜡样芽孢杆菌的PI-PLC的基因序列,按照大肠杆菌的密码子偏好性进行密码子优化,合成相应基因序列并构建基因表达载体pGEX-6P-1-PI-PLC。将重组质粒转入受体菌E.coli BL21(DE3)中,通过加入异丙基硫代-β-D-半乳糖苷(IPTG)诱导目的基因PI-PLC表达。经检测,含有GST标签的PI-PLC融合蛋白以可溶蛋白形式存在于菌体破碎上清,分子量约为61 kDa,与预期相符。初步优化诱导表达条件后,发现最佳诱导表达条件为:以接种量5%接种体积分数接种,待菌体生长至OD600nm达到0.5,在16℃条件下以0.3 mmol/L浓度IPTG诱导24 h。利用GST标签对蛋白进行纯化,纯化后的PI-PLC质量浓度为0.52 mg/mL,比酶活为1322.5 U/mg。利用PI-PLC酶液对哺乳动物细胞表面的模式GPI锚定蛋白CD59进行酶切,酶切作用显著。因此,下一步可以将PI-PLC融合蛋白应用于细胞生物学中对GPI-APs的研究和鉴定。     

以MMP酶切位点为连接臂构建Vasostatin和TRAIL的融合蛋白及其生物学活性分析

以基质金属蛋白酶(MMP)酶切位点（PLGLWA）为连接臂,采用重组PCR技术获得血管形成抑制素(vasostatin,V）和肿瘤坏死因子相关凋亡诱导配体(TRAIL,T）的融合蛋白质编码序列,将该融合编码序列插入原核表达载体pMAL-c2中,重组质粒转化大肠杆菌BL21,IPTG诱导表达,分别得到MBP-VT和MBP-TV融合蛋白,Amylose Resin亲和层析柱纯化.初步纯化的融合蛋白MBP-VT在体外内皮细胞增殖抑制实验、肿瘤细胞凋亡诱导实验中显示了明显的活性,而MBP-TV的作用不明显;体外酶切实验和培养肿瘤细胞上清酶切融合蛋白的免疫印迹分析,证实融合蛋白MBP-VT皆能被正确酶切.上述结果表明成功表达了融合蛋白VT,该融合蛋白具有双重抗肿瘤活性,并可在肿瘤高表达的MMP作用下裂解为V和T.     

重组人βNGF在大肠杆菌中的可溶表达、纯化及活性鉴定

旨在大肠杆菌中可溶表达重组人神经生长因子(Recombinant humanβnerve growth factor,rhβNGF),并对表达产物进行分离纯化和生物学活性鉴定。成功扩增h NGFβ亚基基因,将其克隆入pMAL-c2X表达载体,构建了hβNGF-MBP的大肠杆菌表达体系并进行诱导表达,表达产物经纯化后以Factor Xa酶切去除麦牙糖结合蛋白(MBP),Western blot鉴定后以TF-1细胞法检测生物学活性。结果显示,pMAL-c2X-hβNGF经酶切和测序证实构建正确,25℃、180 r/min、0.5 mmol/L IPTG诱导下可溶表达hβNGF-MBP融合蛋白。hβNGF-MBP经Factor Xa酶切后可去除MBP标签,SDS-PAGE分析纯化的hβNGF位于13 k D左右,纯度可达95%。Western blot鉴定为hβNGF,结果表明,比活约为1×10~6 U/mg。在大肠杆菌中成功可溶表达hβNGF,并具有较高的生物学活性。     

A generic protocol for the expression and purification of recombinant proteins in Escherichia coli using a combinatorial His6-maltose binding protein fusion tag

We describe a generic protocol for the overproduction and purification of recombinant proteins in Escherichia coli. The strategy utilizes a dual His6-maltose binding protein (HisMBP) affinity tag that can be removed from the target protein by digestion of the fusion protein at a designed site by tobacco etch virus protease. The MBP moiety serves to enhance the solubility and promote the proper folding of its fusion partners, and the polyhistidine tag facilitates its purification to homogeneity. This protocol is divided into three stages, each of which takes approximately 1 week to complete: (i) construction of a HisMBP fusion vector; (ii) a pilot experiment to assess the yield and solubility of the target protein; and (iii) the large-scale production and purification of the target protein.     

结核分枝杆菌H37Rv新基因Rv2742克隆表达及纯化

Rv2742是本课题组前期基于蛋白质基因组学策略从结核分枝杆菌Mycobacteriumtuberculosis H37Rv中发现、鉴定的遗漏注释基因。文中旨在建立结核分枝杆菌H37Rv漏注释蛋白Rv2742的可溶性诱导表达、纯化体系,为进一步探索Rv2742基因参与的生物学功能奠定基础。前期实验发现构建的pGEX-4T-2-Rv2742、pET-28a-Rv2742、pET-32a-Rv2742及pMAL-c2X-Rv2742原核表达载体均无法实现目的蛋白的诱导表达。但经密码子优化后,仅有pMAL-c2X-Rv2742载体能够实现目的蛋白的可溶性诱导表达。此外,通过比较不同宿主菌、温度及IPTG浓度对目的蛋白表达量的影响,发现目的蛋白在Rosetta (DE3)中,16℃及0.5mmol/LIPTG诱导条件下表达量最高。直链淀粉树脂(Amyloseresin)亲和层析柱纯化获得较纯的产物,经LC-MS/MS验证确认是Rv2742融合蛋白肽段序列。成功获得结核分枝杆菌H37Rv新基因Rv2742的重组蛋白,可进一步开展其潜在相互作用及免疫原性研究工作。     

人类博卡病毒(HBoV)非结构蛋白NS1基因的克隆、原核表达及多克隆抗体的制备

目的:克隆、表达、纯化人类博卡病毒(HBoV)非结构蛋白NS1,制备抗NS1多克隆抗体。方法:利用PCR扩增HBoV非结构蛋白NS1基因,将其克隆至pMAL-c2X表达载体上,重组质粒转化大肠杆菌DH10B,IPTG诱导表达。表达的融合蛋白经Amylose Resin亲和层析柱纯化后,免疫新西兰大白兔制备多克隆抗体。用间接ELISA法检测抗体效价。结果:原核表达融合蛋白MBP-NS1,并获得了其多克隆抗体,抗体效价达到1∶32000。结论:在原核表达系统中表达、纯化了融合蛋白,制备抗NS1多克隆抗体,为进一步研究该病毒非结构蛋白基因的转录和翻译机制提供可靠的工具。     

人前列腺特异膜抗原膜外区基因的克隆表达及抗体的制备

利用RT PCR技术 ,从前列腺癌组织总RNA中扩增人前列腺特异膜抗原 (PSMA)基因编码区序列 ,克隆至pcDNA3.1载体 ,以此为模板再次PCR扩增出PSMA膜外区cDNA(edPSMA) ,序列测定表明克隆获得的PSMA及edPSMA与基因库所登录的序列相一致。构建原核表达质粒pMAL c2x edPSMA ,经IPTG诱导表达的MBP edPSMA融合蛋白分子量约 12 0kD ,Westernblot证实表达产物可特异地与PSMA单克隆抗体 4G5结合。用直链淀粉琼脂糖凝胶 (Amyloseresin)亲和层析纯化蛋白质可得到电泳均一的融合蛋白 ,免疫BALB C小鼠制备多抗 ,获得效价为 1∶12 80 0的多克隆抗体 ,该抗体可用于前列腺癌组织标本PSMA表达的检测     

A dual protease approach for expression and affinity purification of recombinant proteins

We describe a new method for affinity purification of recombinant proteins using a dual protease protocol. Escherichia coli maltose binding protein (MBP) is employed as an N-terminal tag to increase the yield and solubility of its fusion partners. The MBP moiety is then removed by rhinovirus 3C protease, prior to purification, to yield an N-terminally His₆-tagged protein. Proteins that are only temporarily rendered soluble by fusing them to MBP are readily identified at this stage because they will precipitate after the MBP tag is removed by 3C protease. The remaining soluble His₆-tagged protein, if any, is subsequently purified by immobilized metal affinity chromatography (IMAC). Finally, the N-terminal His₆ tag is removed by His₆-tagged tobacco etch virus (TEV) protease to yield the native recombinant protein, and the His₆-tagged contaminants are removed by adsorption during a second round of IMAC, leaving only the untagged recombinant protein in the column effluent. The generic strategy described here saves time and effort by removing insoluble aggregates at an early stage in the process while also reducing the tendency of MBP to “stick” to its fusion partners during affinity purification.     

An Escherichia coli vector to express and purify foreign proteins by fusion to and separation from maltose-binding protein

A plasmid vector has been constructed that directs the synthesis of high levels (approximately 2% of total cellular protein) of fusions between a target protein and maltose-binding protein (MBP) in Escherichia coli. The MBP domain is used to purify the fusion protein in a one step procedure by affinity chromatography to crosslinked amylose resin. The fusion protein contains the recognition sequence (Ile-Glu-Gly-Arg) for blood coagulation factor Xa protease between the two domains. Cleavage by factor Xa separates the two domains and the target protein domain can then be purified away from the MBP domain by repeating the affinity chromatography step. A prokaryotic (beta-galactosidase) and a eukaryotic (paramyosin) protein have been successfully purified by this method.     

Construction of intein-mediated hGMCSF expression vector and its purification in Pichia pastoris

As a novel attempt for the intracellular recombinant protein over expression and easy purification from Pichia pastoris, the therapeutic cytokine human granulocyte macrophage colony stimulating factor (hGMCSF) gene was fused to an intein-chitin-binding domain (gene from pTYB11 vector) fusion tag by overlap extension PCR and inserted into pPICZB vector, allowing for the purification of a native recombinant protein without the need for enzymatic cleavage. The fusion protein under the AOX1 promoter was integrated into the P. pastoris genome (SMD 1168) and the recombinant Pichia clones were screened for multicopy integrants. Expression of hGMCSF was done using glycerol and methanol based synthetic medium by three stage cultivation in a bioreactor. Purification of the expressed hGMCSF fusion protein was done after cell disruption and binding of the solubilized fusion protein to chitin affinity column, followed by DTT induced on column cleavage of hGMCSF from the intein tag. In this study, final biomass of 89 g dry cell weight/l and purified hGMCSF of 120 mg/l having a specific activity of 0.657 x 10(7) IU/mg was obtained. This strategy has an edge over the other--His or--GST based fusion protein purification where non-specific protein binding, expensive enzymatic cleavage and further purification of the enzyme is required. It distinguishes itself from all other purification systems by its ability to purify, in a single chromatographic step.